期刊文献+

神经内分泌肿瘤68Ga-DOTA-NOC肝脏和胰腺摄取变异性研究 被引量:1

下载PDF
导出
摘要 目的:探讨胰腺和肝脏摄取68Ga-DOTA-NOC的规律,用于早期诊断胰腺神经内分泌肿瘤(pancreatic neuroendocrine tumor,pNET)。方法:回顾性收集70例符合要求的68Ga-DOTA-NOC PET/CT受检者资料,分为全身显像阴性组(A组,53例)和胰腺原发单个病灶神经内分泌肿瘤组(B组,17例),A组依据有、无肿瘤病史再分为C组和D组,进行体积感兴趣区(volume regions of interest,vROI)勾画,获得最大标准摄取值(maximum of standard uptake value,SUVmax)。结果:病灶SUVmax=26.34±17.31,胰钩突SUVmax=8.46±4.29,胰体尾SUVmax=2.38±0.66。B组、C组和D组肝脏的SUVmax值分别为7.31±1.89、8.60±1.99和9.75±2.94,单因素方差分析:F=5.047,P=0.009,组间差异有统计学意义。结论:病灶、胰腺和肝脏摄取68Ga-DOTA-NOC的SUVmax值是较好的临床评估界值。
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2019年第7期1044-1047,共4页 Journal of Nanjing Medical University(Natural Sciences)
基金 国家自然科学基金(81271604) 江苏科技创新与成果转化专项引导资金项目(BL2012037) 南京医学科技发展项目(YKK14089) CSCO-神经内分泌肿瘤发展基金(YN2014-004) 南京医科大学科技发展基金(2014NJMU046)
  • 相关文献

参考文献4

二级参考文献47

  • 1Chun Ye,Peng-Cheng xi,Xian-Gui Hu the Department of General Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.Clinical analysis of uncinate process carcinoma of the pancreas[J].Hepatobiliary & Pancreatic Diseases International,2003,2(4):605-608. 被引量:3
  • 2Sen Li,Yong-Quan Pei,Fu-Tian Du,Guan-Yi Zhuang,Chun-You Li,Qin-Hua Song,Wei Ding,Jian-Li Wang the Department of Hepatobiliary Surgery, Weifang People’s Hospital, Weifang 261041, China.Surgical treatment for uncinate process carcinoma of the pancreas[J].Hepatobiliary & Pancreatic Diseases International,2002,1(4):592-594. 被引量:1
  • 3Srinivas R Puli,Nikhil Kalva,Matthew L Bechtold,Smitha R Pamulaparthy,Micheal D Cashman,Norman C Estes,Richard H Pearl,Fritz-Henry Volmar,Sonu Dillon,Michael F Shekleton,David Forcione.Diagnostic accuracy of endoscopic ultrasound in pancreatic neuroendocrine tumors: A systematic review and meta analysis[J].World Journal of Gastroenterology,2013,19(23):3678-3684. 被引量:16
  • 4Neoptolemos JP,Stocken DD,Friess H,et al.A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancerNew England Journal of Homeopathy,2004.
  • 5Pappas S, Federle MP, Lokshin AE, et al. Early detection and staging of adenocarcinoma of the pancreas. Gastroenterol Clin North Am, 2007, 36: 413-429.
  • 6De Martino MC, Hofland LJ, Lamberts SW. Somatostatin and som- atostatin receptors: from basic concepts to clinical applications. Prog Brain Res, 2010, 182: 255-280.
  • 7Msaouel P, Galanis E, Koutsilieris M. Somatostatin and somatosta-tin receptors : implications for neoplastic growth and cancer biology. Expert Opin Investig Drugs, 2009, 18: 1297-1316.
  • 8Wang F, Wang Z, Yao W, et al. Role of 99Tcm-octreotide acetate scintigraphy in suspected lung cancer compared with tSF-FDG dual- head coincidence imaging. J Nucl Med, 2007, 48: 1442-1448.
  • 9Krantic S. Peptides as regulators of the immuse system: emphasis on somatostatin. Peptides, 2000, 21: 1941-1946.
  • 10Oberg KE. The management of neuroendocrine tumours: current and future medical therapy options. Clin Oncol ( R Coil Radiol), 2012, 24: 282-293.

共引文献26

同被引文献6

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部